May 22, 2024

Oral Typhoid Vaccine Market driven by growing awareness regarding benefits of vaccination

The global Oral Typhoid Vaccine Market is estimated to be valued at US$ 394.62 Bn in 2023 and is expected to exhibit a CAGR of 12% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Typhoid fever is a severe, life-threatening bacterial infection caused by Salmonella Typhi. Oral typhoid vaccines help prevent typhoid fever by exposing the body to Salmonella Typhi bacteria in a form that cannot cause disease but allows the body’s immune system to recognize and fight against the germs. The demand for oral typhoid vaccines is growing due to increasing awareness regarding the benefits of vaccination against typhoid fever. Oral vaccines are an effective and easy way for mass immunization against typhoid, as they do not require trained healthcare professionals for administration. The risk of typhoid is high in developing countries with poor sanitation and limited access to clean drinking water. Oral vaccination programs are being conducted in these regions to control the disease burden and its economic impact. Moreover, the oral dosage of the vaccine makes administration inexpensive and improves compliance.

The global Oral Typhoid Vaccine Market is estimated to be valued at US$ 394.62 Bn in 2023 and is expected to exhibit a CAGR of 12% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
One of the key trends in the oral typhoid vaccine market is the development of next-generation oral typhoid vaccines with improved immunogenicity and longer durability of protection. For instance, Bharat Biotech introduced Vivotif, an advanced live-attenuated oral typhoid vaccine, in 2009. Vivotif has proven to induce stronger immune responses and provide longer-lasting protection of 3-5 years compared to the previous generation capsule vaccine Ty21a. Moreover, companies are focusing on developing affordable oral typhoid vaccines for mass vaccination campaigns in low- and middle-income countries where the disease burden is highest. This is driving the adoption of oral typhoid vaccination programs globally.

Porter’s Analysis
Threat of new entrants: The oral typhoid vaccine market has moderate threat from new entrants due to established players and required regulatory approvals. However, new advanced technologies can help new players enter the market.
Bargaining power of buyers: Individual buyers have low bargaining power due to medical necessity of vaccines. However, government organizations and private players have moderate bargaining power due to volume-based purchasing.
Bargaining power of suppliers: Suppliers of active ingredients and packaging materials have moderate bargaining power due to specialized manufacturing requirements of vaccines.
Threat of new substitutes: There is low-medium threat from substitutes as oral vaccines provide an alternative method of administration compared to injectables with potential for improved patient compliance.
Competitive rivalry: The oral typhoid vaccine market is highly competitive with focus on R&D, production capacity expansion, and portfolio expansion through collaborations.

Key Takeaways
The global oral typhoid vaccine market is expected to witness high growth during the forecast period of 2023 to 2030.

Regional analysis – The Asia Pacific region currently dominates the market and is expected to witness the highest growth over the forecast period due to a large patient population and improvements in healthcare systems in various countries.

Key players operating in the oral typhoid vaccine market are Sanofi Pasteur, Bharat Biotech, Pfizer Inc., GlaxoSmithKline (GSK), Baxter International Inc., Merck & Co., Inc. (MSD outside North America), Takeda Pharmaceutical Company Limited, Novartis International AG, Biological E. Limited, AstraZeneca, Cipla Limited, Prokarium, Bio-Med Pvt. Ltd., Panacea Biotec, Dynavax Technologies Corporation, Butantan Institute, Zydus Cadila, Biomed Pvt. Ltd., Cadila Healthcare Limited, GlaxoSmithKline Biologicals.

*Note:

  1. Source: Coherent Market Insights, Public sources, Desk research
  2. We have leveraged AI tools to mine information and compile it